2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Microbiome as an endocrine organ and its relationship with eye diseases: Effective factors and new targeted approaches

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Microbiome is an endocrine organ that refers to both the complicated biological system of microbial species that colonize our bodies and their genomes and surroundings. Recent studies confirm the connection between the microbiome and eye diseases, which are involved in the pathogenesis of eye diseases, including age-related macular disorders, diabetic retinopathy, glaucoma, retinitis pigmentosa, dry eye, and uveitis. The aim of this review is to investigate the microbiome in relation to eye health. First, a brief introduction of the characteristics of the gut microorganisms terms of composition and work, the role of dysbiosis, the gut microbiome and the eye microbiome in the progression of eye illnesses are highlighted, then the relationship among the microbiome and the function of the immune system and eye diseases, the role of inflammation and aging and the immune system, It has been reviewed and finally, the control and treatment goals of microbiome and eye diseases, the role of food factors and supplements, biotherapy and antibiotics in relation to microbiome and eye health have been reviewed.

          Related collections

          Most cited references166

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics

          With the continued interest in the role of the gut microbiota in health, attention has now turned to how to harness the microbiota for the benefit of the host. This Consensus Statement outlines the definition and scope of the term 'prebiotic' as determined by an expert panel convened by the International Scientific Association for Probiotics and Prebiotics in December 2016.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity.

            Obesity and type 2 diabetes are characterized by altered gut microbiota, inflammation, and gut barrier disruption. Microbial composition and the mechanisms of interaction with the host that affect gut barrier function during obesity and type 2 diabetes have not been elucidated. We recently isolated Akkermansia muciniphila, which is a mucin-degrading bacterium that resides in the mucus layer. The presence of this bacterium inversely correlates with body weight in rodents and humans. However, the precise physiological roles played by this bacterium during obesity and metabolic disorders are unknown. This study demonstrated that the abundance of A. muciniphila decreased in obese and type 2 diabetic mice. We also observed that prebiotic feeding normalized A. muciniphila abundance, which correlated with an improved metabolic profile. In addition, we demonstrated that A. muciniphila treatment reversed high-fat diet-induced metabolic disorders, including fat-mass gain, metabolic endotoxemia, adipose tissue inflammation, and insulin resistance. A. muciniphila administration increased the intestinal levels of endocannabinoids that control inflammation, the gut barrier, and gut peptide secretion. Finally, we demonstrated that all these effects required viable A. muciniphila because treatment with heat-killed cells did not improve the metabolic profile or the mucus layer thickness. In summary, this study provides substantial insight into the intricate mechanisms of bacterial (i.e., A. muciniphila) regulation of the cross-talk between the host and gut microbiota. These results also provide a rationale for the development of a treatment that uses this human mucus colonizer for the prevention or treatment of obesity and its associated metabolic disorders.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Introduction to the human gut microbiota

              The human gastrointestinal (GI) tract harbours a complex and dynamic population of microorganisms, the gut microbiota, which exert a marked influence on the host during homeostasis and disease. Multiple factors contribute to the establishment of the human gut microbiota during infancy. Diet is considered as one of the main drivers in shaping the gut microbiota across the life time. Intestinal bacteria play a crucial role in maintaining immune and metabolic homeostasis and protecting against pathogens. Altered gut bacterial composition (dysbiosis) has been associated with the pathogenesis of many inflammatory diseases and infections. The interpretation of these studies relies on a better understanding of inter-individual variations, heterogeneity of bacterial communities along and across the GI tract, functional redundancy and the need to distinguish cause from effect in states of dysbiosis. This review summarises our current understanding of the development and composition of the human GI microbiota, and its impact on gut integrity and host health, underlying the need for mechanistic studies focusing on host–microbe interactions.
                Bookmark

                Author and article information

                Contributors
                Journal
                World J Gastrointest Pathophysiol
                WJGP
                World Journal of Gastrointestinal Pathophysiology
                Baishideng Publishing Group Inc
                2150-5330
                22 September 2024
                22 September 2024
                : 15
                : 5
                : 96446
                Affiliations
                Department of Clinical Bioinformatics, Harvard Medical School, Boston, MA 02115, United States. leilahagh@ 123456yahoo.com
                Department of Bioscience, School of Science and Technology, Nottingham Trend University, Nottingham NG1 4FQ, United Kingdom
                Department of Microbiology, Saveh University of Medical Sciences, Saveh 3919676651, Iran
                Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Catania, Italy
                Department of Neuroimmunology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, United States
                Department of Human Nutrition and Food Sciences, Texas Women University, Milano 20154, Italy
                Author notes

                Co-corresponding authors: Leila Haghshenas and Francesco Marotta.

                Author contributions: Haghshenas L has cooperated in all aspects of writing and sending the article for publishing and corrections; Banihashemi S and Malekzadegan Y have cooperated in the selection of figures and content analysis; Ahmadi AM has cooperated in writing the text; Catanzaro R and Marotta F have cooperated in reviewing and approving the article and guiding the topic and selecting the reference of articles.

                Corresponding author: Leila Haghshenas, PhD, Assistant Professor, Department of Clinical Bioinformatics, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, United States. leilahagh@ 123456yahoo.com

                Article
                jWJGP.v15.i5.eid96446 96446
                10.4291/wjgp.v15.i5.96446
                11440246
                39355345
                87e1fa49-cbd7-43fa-8237-7315da80efb9
                ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

                This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

                History
                : 7 May 2024
                : 4 September 2024
                : 13 September 2024
                Categories
                Review

                dysbiosis,gut microbiome,eye diseases,inflammation,diabetic retinopatyhy,aging,nutrient supplementation

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content236

                Most referenced authors2,996